Wilson M, McDade C, Thiruvillakkat K, Rouse R, Sivamurthy K, Yan S. Long-term impact of the gene therapy etranacogene dezaparvovec for the treatment of hemophilia B in the United States. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S36-7.
Fan Q, Hawe E, Yang J, Burgess B, Bullano M, Mokdad A. Cost outcomes of noninhibitor patients with hemophilia A switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies in the United States. Poster presented at the AMCP Nexus 2023; October 16, 2023. Orlando, FL. [abstract] J Manag Care Pharm. 2023 Oct; 29(10-a Suppl):S35.
Chinthammit C, Mody R, Aguado J, Meyers J. Does weight loss in addition to HbA1c reduction impact health care costs in patients treated with T2D? a retrospective database analysis. Poster presented at the AMCP 2023 Annual Meeting; March 21, 2023. San Antonio, TX. [abstract] J Manag Care Pharm. 2023 Mar; 29(10-2):S27.